NANOVIRICIDES, INC. Stock-Based Compensation
NANOVIRICIDES, INC. (NNVC) reported Stock-Based Compensation of $563 for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-09-27
- NANOVIRICIDES, INC. share-based payment arrangement, expense for fiscal 2024 was $563.00, a 98.72% decline from fiscal 2023.
- NANOVIRICIDES, INC. share-based payment arrangement, expense for fiscal 2023 was $44.00K.
- NANOVIRICIDES, INC. share-based payment arrangement, expense for fiscal 2021 was $0.00.
- NANOVIRICIDES, INC. share-based payment arrangement, expense for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Share-based Payment Arrangement, Expense 12 month |
|---|---|
| 2024-06-30 | $563.00 10-K · filed 2024-09-27 |
| 2023-06-30 | $44.00K 10-K · filed 2024-09-27 |
| 2021-06-30 | $0.00 10-K · filed 2021-10-12 |
| 2020-06-30 | $0.00 10-K · filed 2020-10-13 |
| 2019-06-30 | $11.92K 10-K · filed 2021-10-12 |
| 2018-06-30 | $16.77K 10-K · filed 2018-10-12 |
| 2009-06-30 | $7.04K 10-Q/A · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |